Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).

Tadaaki Yamada Uchino JunjiYusuke ChiharaTakayuki ShimamotoMasahiro IwasakuNobuyo TamiyaYoshiko KanekoFumiaki KiyomiKoichi Takayama

Published in: Therapeutic advances in medical oncology (2020)

We are conducting an intervention study to investigate the safety and efficacy of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy.

Keyphrases

small cell lung cancer
combination therapy
randomized controlled trial
rectal cancer
locally advanced
advanced non small cell lung cancer
squamous cell carcinoma
clinical trial
radiation induced
replacement therapy
epidermal growth factor receptor